mesalazine

(redirected from Mezavant)
Also found in: Dictionary.

mesalamine

 [mĕ-sal´ah-mēn]
an active metabolite of sulfasalazine, used in prophylaxis and treatment of inflammatory bowel disease; administered orally or rectally. Called also 5-aminosalicylic acid.

mesalamine (5-aminosalicylic acid, 5-ASA, mesalazine, mesalazine (UK))

Apriso, Asacol, Asacol HD, Canasa, Ipocol (UK), Lialda, Mesasal (CA), Mesren (UK), Mezavant (CA), Novo-5-ASA-Ect (CA), Pentasa, Rowasa, Salofalk (CA) (UK)

Pharmacologic class: 5-amino-2-hydroxybenzoic acid

Therapeutic class: GI anti-inflammatory drug

Pregnancy risk category B

Action

Unknown. Thought to act in colon, where it blocks cyclooxygenase and inhibits prostaglandin synthesis.

Availability

Capsules (extended-release): 250 mg, 500 mg, 0.375 g (Apriso)

Rectal suspension: 4 g/60 ml

Suppositories: 1,000 mg

Tablets (delayed-release): 400 mg (Pentasa), 800 mg (Asacol HD), 1.2 g (Lialda)

Indications and dosages

Active ulcerative colitis

Adults: 800 mg P.O. (Asacol delayed-release tablets) t.i.d. for 6 weeks

To induce remission in mildly to moderately active ulcerative colitis

Adults: 1 g P.O. (Pentasa extended-release capsules) q.i.d. for a total dosage of 4 g daily for up to 8 weeks. Or, two to four 1.2 g (Lialda) extended-release tablets P.O. once daily for total daily dose of 2.4 or 4.8 g for up to 8 weeks.

Active distal ulcerative colitis, proctosigmoiditis, or proctitis

Adults: 4-g enema (Rowasa 60 ml) P.R. daily at bedtime, retained for 8 hours. Continue for 3 to 6 weeks.

Active ulcerative proctitis

Adults: 500 mg (Canasa suppository) P.R. b.i.d., increased to t.i.d. if response inadequate after 2 weeks. Or 1,000 mg (suppository) P.R. at bedtime, continued for 3 to 6 weeks.

To maintain remission of ulcerative colitis

Adults: 1.6 g (Asacol) P.O. daily in divided doses. Or, 1.5 g (Apriso) P.O. daily in the morning.

Contraindications

• Hypersensitivity to drug, its components, or salicylates

Precautions

Use cautiously in:
• severe hepatic or renal impairment
• allergy to sulfasalazine
• pyloric stenosis (delayed-release tablets)
• conditions predisposing to development of myocarditis or pericarditis
• pregnant or breastfeeding patients
• children younger than age 18 (safety and efficacy not established).

Administration

• Give Apriso capsules with or without food. Don't give concurrently with antacids.
• Give Lialda tablets with meal.
• Make sure patient swallows tablets whole without crushing or chewing.
• For best effect, have patient retain suppository for 1 to 3 hours.

Adverse reactions

CNS: headache, dizziness, malaise, weakness

CV: chest pain, mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis)

EENT: rhinitis, pharyngitis

GI: nausea, vomiting, diarrhea, eructation, flatulence, anal irritation (with rectal use), pancreatitis

GU: interstitial nephritis, renal failure

Musculoskeletal: back pain

Skin: alopecia, rash

Other: fever, acute intolerance syndrome, anaphylaxis, acute intolerance syndrome

Interactions

Drug-drug.Antacids: increased risk of dissolution of coating of Apriso granules

Azathioprine, 6-mercaptopurine: increased potential for blood disorders

Nephrotoxic drugs (including nonsteroidal anti-inflammatory agents): increased risk of renal adverse reactions

Patient monitoring

Monitor carefully for mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis).

Closely monitor patients with history of allergic reactions to sulfasalazine or sulfite sensitivity (if using enema).
• Assess kidney and liver function before and periodically during therapy.
• Monitor for suppository efficacy, which should appear in 3 to 21 days. However, know that treatment usually continues for 3 to 6 weeks.

Watch for signs and symptoms of intolerance syndrome, such as cramping, acute abdominal pain, bloody diarrhea, fever, headache, and rash. If these occur, discontinue drug and notify prescriber.

Watch for signs and symptoms of intolerance syndrome, such as cramping, acute abdominal pain, bloody diarrhea, fever, headache, and rash. If these occur, discontinue drug. Drug may be restarted later only if clearly needed, under close medical supervision and at reduced dosage.

Patient teaching

• Instruct patient to swallow tablets or capsules whole.
• Tell patient to contact prescriber if partially intact tablets repeatedly appear in stools.
• Advise patient using suppository to avoid excessive handling and to retain suppository for 1 to 3 hours or longer for maximum benefit.
• Teach patient about proper enema administration. Tell him to stay in position for at least 30 minutes and, if possible, retain medication overnight.

Advise patient to immediately report breathing difficulties, allergic symptoms, cramping, acute abdominal pain, bloody diarrhea, fever, headache, or rash.
• As appropriate, review all other significant and life-threatening adverse reactions, especially those related to the drugs mentioned above.

mesalazine

/me·sal·a·zine/ (mĕ-sal´ah-zēn) mesalamine.

mesalazine

A salicylate drug used to treat, and prevent recurrences of, ULCERATIVE COLITIS. Brand names are Asacol, Pentasa and Salofalk.

mesalazine, mesalamine

5-aminosalicylic acid; the active anti-inflammatory component of sulfasalazine when used in the treatment of inflammatory bowel disease. Used orally or rectally as suppositories or enemas.
References in periodicals archive ?
million), LIALDA/ MEZAVANT (up 20% to $634 million), ELAPRASE (up 9%
On June 7, 2011 following approval by Health Canada on February 10, 2011 Shire announced the launch of MEZAVANT for the new expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
Cosmo's first MMX product that has reached the market is Lialda / Mezavant / Mesavancol, a treatment for IBD that is licensed globally to Giuliani and Shire Limited.
FABRAZYME and CEREZYME which are trademarks of Genzyme Corporation, LIALDA and MEZAVANT which are trademarks of Giuliani International Limited and DAYTRANA which is a trade mark of Noven Pharmaceuticals Inc.
VPRIV for the treatment of Type 1 Gaucher disease in the European Union ("EU"); - MEZAVANT for the treatment of ulcerative colitis in certain EU and RoW countries; - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary angiodema ("HAE") in certain European and Latin American countries; - EQUASYM(R) for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD") in certain EU countries; and - VYVANSE (VENVANSE) for the treatment of ADHD in children in Brazil.
VPRIV(TM) for the treatment of Type 1 Gaucher disease in the EU; - REPLAGAL for the treatment of Fabry disease in the US; - MEZAVANT for the treatment of ulcerative colitis in certain EU and RoW countries; - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary angiodema ("HAE") in certain European and Latin American countries; and - EQUASYM(R) for the treatment of ADHD in certain EU countries.
VPRIV(TM) for the treatment of Gaucher disease in the US and EU; - REPLAGAL for the treatment of Fabry disease in the US; - MEZAVANT for the treatment of ulcerative colitis in certain EU and RoW countries; - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary angiodema in certain European and Latin American countries; - EQUASYM(R) for the treatment of ADHD in certain EU countries; and - VYVANSE for the treatment of ADHD in Canada.
Noven")) DERMAGRAFT (Human Fibroblast-Derived Dermal Substitute) ELAPRASE (idursulfase) EQUASYM IR (methylphenidate hydrochloride) EQUASYM XL (methylphenidate hydrochloride) FIRAZYR (icatibant) FOSRENOL (lanthanum carbonate) INTUNIV (guanfacine extended release) JUVISTA (trademark of Renovo Limited ("Renovo")) LIALDA (mesalamine) MEZAVANT (mesalazine) PENTASA (trademark of Ferring B.
By September 30, 2009 MEZAVANT was available in eight countries outside the US, and further launches are planned in other countries throughout 2009 and 2010, subject to the successful conclusion of pricing and reimbursement negotiations.